| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/22/2001 | WO2001020025A2 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 03/22/2001 | WO2001020004A2 Protein phosphatase and kinase proteins |
| 03/22/2001 | WO2001019983A1 Human g-protein coupled receptor |
| 03/22/2001 | WO2001019977A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 03/22/2001 | WO2001019966A2 Isolation of muscle-derived stem cells and uses therefor |
| 03/22/2001 | WO2001019960A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic |
| 03/22/2001 | WO2001019868A1 A novel angiogenesis inhibitor |
| 03/22/2001 | WO2001019861A2 Apo-2 receptor antibodies |
| 03/22/2001 | WO2001019860A2 Proteins associated with cell differentiation |
| 03/22/2001 | WO2001019856A2 Secreted human proteins, polynucleotides encoding them and methods of using the same |
| 03/22/2001 | WO2001019852A2 Methods of peptide preparation |
| 03/22/2001 | WO2001019850A2 Nrage nucleic acids and polypeptides and uses thereof |
| 03/22/2001 | WO2001019847A1 A binding motif of a receptor |
| 03/22/2001 | WO2001019846A1 Transgenically produced fusion proteins |
| 03/22/2001 | WO2001019842A1 Subunit optimized fusion proteins |
| 03/22/2001 | WO2001019839A1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| 03/22/2001 | WO2001019831A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 03/22/2001 | WO2001019830A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 03/22/2001 | WO2001019829A2 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | WO2001019828A2 Kinase inhibitors as therapeutic agents |
| 03/22/2001 | WO2001019826A2 Triazolopyrimidine derivatives |
| 03/22/2001 | WO2001019825A1 Pteridinones as kinase inhibitors |
| 03/22/2001 | WO2001019824A2 New active marine alkaloids |
| 03/22/2001 | WO2001019823A2 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 03/22/2001 | WO2001019819A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | WO2001019814A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | WO2001019810A1 Water-soluble cephalomannine esters with poly-amino-acid or the salts thereof, pharmaceutical compositions containing them and their use in medicine |
| 03/22/2001 | WO2001019801A1 Bioactive substance containing derivatives of 2-amino-6-aryloxypyrimidines and intermediary products of synthesis thereof |
| 03/22/2001 | WO2001019800A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 03/22/2001 | WO2001019794A2 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
| 03/22/2001 | WO2001019791A2 3-vinylpyrrole derivatives, method for the production thereof and their use as medicaments |
| 03/22/2001 | WO2001019770A2 Rxr modulators with improved pharmacologic profile |
| 03/22/2001 | WO2001019542A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 03/22/2001 | WO2001019408A1 Nucleic acids encoding polyepitope polypeptides |
| 03/22/2001 | WO2001019407A2 Taxane prodrugs |
| 03/22/2001 | WO2001019406A2 Amphiphilic prodrugs |
| 03/22/2001 | WO2001019399A2 Method of potentiating chemotherapy and treating solid tumors |
| 03/22/2001 | WO2001019397A1 Methods and compositions utilizing rad51 |
| 03/22/2001 | WO2001019388A1 Medicament containing contactinhibin and medicament containing antibodies directed against contactinhibin |
| 03/22/2001 | WO2001019387A1 Use of mullerian inhibiting substance for treating excess androgen states |
| 03/22/2001 | WO2001019380A2 Oncolytic virus |
| 03/22/2001 | WO2001019372A1 Formulations for parenteral use of estramustine phosphate and amino acids |
| 03/22/2001 | WO2001019369A1 Use of thienopyrimidines |
| 03/22/2001 | WO2001019361A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 03/22/2001 | WO2001019360A2 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| 03/22/2001 | WO2001019353A2 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth |
| 03/22/2001 | WO2001019341A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 03/22/2001 | WO2001019339A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | WO2001019338A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 03/22/2001 | WO2001019320A2 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | WO2001019182A1 Nuclear transfer with selected donor cells |
| 03/22/2001 | WO2001005435A3 Antisense therapy for hormone-regulated tumors |
| 03/22/2001 | WO2001000811A3 17867, a novel human aminopeptidase |
| 03/22/2001 | WO2000078341A8 A method for the prophylaxis and/or treatment of medical disorders |
| 03/22/2001 | WO2000074629A3 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal |
| 03/22/2001 | WO2000073323A3 Adam polynucleotides and polypeptides |
| 03/22/2001 | WO2000071693A3 Method for selecting improved vectors |
| 03/22/2001 | WO2000069862A3 Hemisynthetic method and intermediates thereof |
| 03/22/2001 | WO2000059943A3 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE |
| 03/22/2001 | WO2000059899A8 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 03/22/2001 | WO2000055318A3 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 03/22/2001 | WO2000055155A3 Heterocyclic compounds as adenosine deaminase inhibitors |
| 03/22/2001 | WO2000040612A9 Insulin-like growth factor (igf) i mutant variants |
| 03/22/2001 | WO2000040576A3 Thiopyran compounds as inhibitors of mmp |
| 03/22/2001 | WO2000035469A9 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER |
| 03/22/2001 | WO2000018421A9 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 03/22/2001 | WO1999058678A9 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 03/22/2001 | DE19944604A1 Aminderivate Amine derivatives |
| 03/22/2001 | DE19944404A1 Mittel zur Therapie von menschlichen Erkrankungen, insbesondere für die Therapie von Tumoren wie Kolonkarzinomen und Melanomen oder zur Geweberegeneration und Förderung des Haarwuchses Means for therapy of human disease, in particular for the treatment of tumors such as colon carcinoma and melanoma, or for tissue regeneration and promote hair growth |
| 03/22/2001 | DE10036855A1 Neue kristalline Form von 6-Hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophenhydrochlorid New crystalline form of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride |
| 03/22/2001 | DE10031122A1 Composition for the treatment of malignant diseases comprises agents that reduce concentration of YB-1 protein or inhibit its translocation in tumor cells |
| 03/22/2001 | CA2393896A1 Pteridinones as kinase inhibitors |
| 03/22/2001 | CA2388383A1 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth |
| 03/22/2001 | CA2387123A1 Use of thienopyrimidines |
| 03/22/2001 | CA2386559A1 Isolation of muscle-derived stem cells and uses therefor |
| 03/22/2001 | CA2386525A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 03/22/2001 | CA2385769A1 Kinase inhibitors as therapeutic agents |
| 03/22/2001 | CA2385747A1 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | CA2385234A1 Nrage nucleic acids and polypeptides and uses thereof |
| 03/22/2001 | CA2385065A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | CA2385063A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 03/22/2001 | CA2384991A1 Use of mullerian inhibiting substance for treating excess androgen states |
| 03/22/2001 | CA2384987A1 Nucleic acids encoding polyepitope polypeptides |
| 03/22/2001 | CA2384783A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | CA2384782A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | CA2384766A1 Subunit optimized fusion proteins |
| 03/22/2001 | CA2384762A1 Apo-2 receptor antibodies |
| 03/22/2001 | CA2384749A1 Novel human proteins, polynucleotides encoding them and methods of using the same |
| 03/22/2001 | CA2384733A1 Methods and compositions utilizing rad51 |
| 03/22/2001 | CA2384726A1 Formulations for parenteral use of estramustine phosphate and amino acids |
| 03/22/2001 | CA2384656A1 New active marine alkaloids |
| 03/22/2001 | CA2384646A1 Taxane prodrugs |
| 03/22/2001 | CA2384645A1 Amphiphilic prodrugs |
| 03/22/2001 | CA2384324A1 Proteins associated with cell differentiation |
| 03/22/2001 | CA2384081A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic |
| 03/22/2001 | CA2383988A1 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
| 03/22/2001 | CA2383927A1 Protein phosphatase and kinase proteins |
| 03/22/2001 | CA2383565A1 Rxr modulators with improved pharmacologic profile |
| 03/22/2001 | CA2383402A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 03/22/2001 | CA2383177A1 Human g-protein coupled receptor |